Under construction – not a live service
Sign in
Taking people in United StatesNo phase

Testing group therapies to reduce suicidal behavior in bipolar disorder

Tests group therapy programs in adults with bipolar disorder at risk of suicidal behavior.

Plain-language title generated from the registry record
Registry title: Suicidal Behavior in Patients Diagnosed With Bipolar Disorder

Key facts

Where
Atlanta, United StatesSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Source: NCT02604277, who can take part

Where in United States

  • Grady Health SystemAtlanta, United StatesTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Emory University
Trial code
NCT02604277
Record updated
7 January 2026
Original description
The purpose of this study is to learn the environmental and psychological factors that impact suicidality in patients diagnosed with Bipolar Disorder. Additionally, the study aims to identify treatments to reduce the suicidal behavior and improve quality of life through a 6-week group-based intervention program.Read full original descriptionShow less

Suicidal Behavior in Patients Diagnosed With Bipolar Disorder: The Roles of Biological and Childhood and Adult Environmental Risk Factors

The purpose of this study is to learn the environmental and psychological factors that impact suicidality in patients diagnosed with Bipolar Disorder. Additionally, the study aims to identify treatments to reduce the suicidal behavior and improve quality of life through a 6-week group-based intervention program.

Inclusion: English speaking; Diagnosis of Bipolar Disorder (BD); Able to provide written informed consent.

Exclusion: History of schizophrenia spectrum disorder; History of mood incongruent psychotic symptoms; History of primary substance disorder; History of primary organic disease and/or dementia; Cognitive impairments; Acutely psychotic; Medically unstable.

ClinicalTrials.gov NCT02604277